神奈川県立がんセンター臨床研究所
お問い合わせ

がん分子病態学部

当研究所について
研究活動
基礎的技術支援コアセンター
共同研究したい
学生として研究したい
研究員として働きたい
情報セキュリティポリシー
公的研究費の適正管理
交通案内
お問い合わせ
病院サイトはこちら

がん分子病態学部について

がん分子病態学部では、がんセンター臨床各科と多数の共同研究を進めると共に、「がん組織における低酸素、脂質欠乏環境を標的とした新規の早期診断マーカー・治療分子標的の開発」、「がん関連血栓塞栓症（CAT）の早期予測マーカー・治療分子標的の探索」、「がん周囲微小環境の多面的理解による、転移進行がんに対する新規がん治療法の開発」、「形態情報・エピゲノム情報のAI解析から作出する新規診断・治療効果予測・予後判定ツールの開発」の4つの研究課題を遂行しています。また、質の高い臨床研究基盤の構築と、それを用いた研究、特に個別化医療の開発研究を促進するために、がんセンター生体試料センターにおける臓器横断的な患者試料バンキングに於いて中心的役割を果たし、また、患者由来異種移植片（Patient Derived Xenograft; PDX）モデルの作製をがん治療学部と共同して進めています。PDXモデルは、希少がんとして、当センターの骨軟部腫瘍と、県立こども医療センターとの連携のもと、小児がんの肺転移巣を移植の対象としています。

研究課題

がん組織における低酸素、脂質欠乏環境を標的とした研究

　がん組織における低酸素、脂質欠乏環境を標的とした研究では、低酸素と共に欠乏する栄養因子との相加、相乗効果でがん細胞に発現が誘導される遺伝子群CD69、ICAM-1、血液凝固第7因子FVII、組織因子TFに焦点を絞って研究を進めています。特に今年度は、卵巣明細胞癌細胞におけるICAM-1依存性アポトーシス抑制機構、特にフィラグリンの役割の解明、さらには明細胞型腎細胞癌にて高発現するICAM-1についてその発現メカニズムに関する研究を遂行しました。現在まで、動物実験によりフィラグリンの腫瘍進展への効果を確認しています。また明細胞型腎細胞癌におけるICAM-1発現は卵巣明細胞癌細胞同様にHIF2a依存的であることなどが明らかにするなどの成果を挙げました。今後の機能解析等を経てICAM-1―フィラグリン経路の治療標的化の可能性を検討予定です。

がん関連血栓塞栓症（CAT）に関する研究

　がん関連血栓塞栓症（CAT）に関する研究では、組織因子の抗原量と凝固活性を膵臓癌患者の血液検体について経時的に測定し、CAT発症患者は発症直前に凝固活性が上昇することを明らかにしました。今後の詳細な研究によりCAT発症メカニズム解明、より正確なCAT発症予測モデルの開発を目指していきます。また、アメロイドコンストリクターを用いて免疫不全マウスの下大静脈を狭窄させることによりCAT研究に有用な新規静脈血栓形成モデルを構築しました。

転移進行がんに対する新規がん治療法の開発研究

　転移進行がんに対する新規がん治療法の開発研究では、引き続き腫瘍微小環境に存在する脂肪細胞・脂肪分泌因子の意義について研究を進めました。前年度に確認した骨転移巣の病理組織学的解析・遺伝子発現解析により明らかにした骨髄脂肪細胞の腫瘍免疫抑制作用、腫瘍関連線維芽細胞誘導促進作用、薬剤抵抗性促進作用について論文に纏め発表しました。また、本研究をin vivoで進めるための選択的骨転移マウスモデルを開発し特許出願を行ないました(特願2024-008814)。がんと脂肪の相互作用研究成果の臨床応用を進めるため、がんと脂肪の相互作用を顕著に認めるがん種（卵巣がん、大腸がん、肉腫）のPDXモデル作製を進め、卵巣がん、大腸がんで安定的なPDX株の樹立に成功しました。さらに本年度は細胞実験、動物実験により、脂肪細胞分泌因子である脂肪分泌因子（アディポカイン）の機能を検討し、がんの増殖・アポトーシスを直接制御するアディポカインを見出しました。現在動物実験によりアディポカインシグナルによる腫瘍増殖制御機構を解析中です。先年度に脂肪前駆細胞からの分化誘導法を作製した特定のアディポカインを分泌する脂肪細胞と合わせて、がん・脂肪相互作用を明らかにし、アディポカインによる転移進行がんの新規治療法開発を目指します。

形態情報・エピゲノム情報のAI解析を基盤とする診断・治療効果予測・予後判定ツールの開発研究

　形態情報・エピゲノム情報のAI解析を基盤とする診断・治療効果予測・予後判定ツールの開発研究では、形態情報のAI解析を行うデジタルデバイスの開発に注力しています。形態解析の際基本となる、ヘマトキシリンエオジン染色標本において着目した病変部と同一座標上の病変を、複数の免疫染色標本においてAI解析により自動的に認識するシステムを開発しました。本システムにより、病理診断における免疫染色の染色性評価が客観的に、精確に行えることが可能になります。本研究成果は職務発明検討会議にて職務発明と認定され、特許出願を行いました。今後、本デジタルデバイスを用いて、AI解析を用いた形態情報の診断・治療への応用の準備、および研究面におけるがん・間質細胞相互作用の形態学的解析への活用を、共同研究を通してさらに進める予定です。

研究論文

2023年

  1. Sato S. Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers. Cell Commun Signal.; 22(1):52, 2024 (Published 2024 Jan 18) IF=8.4
  2. Natsume K, Ye J, Mukai Y, Yamakawa K, Tanimoto M, Ito H, Miyagi Y, Daigo Y, Muto-Ishizuka M, Kadota K, Haba R, Suizu F. Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer. Anticancer Res 44(2):711-722, 2024. (Published 2024 Feb) IF=2.0
  3. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Morita J, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Tryptophanyl-tRNA Synthetase 1 Gene Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res 44(2):673-678, 2024. (Published 2024 Feb) IF=2.0
  4. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Asialoglycoprotein Receptor 2 Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection. Anticancer Res 44(1):397-402, 2024. (Published 2024 Jan) IF=2.0
  5. Kuwatuka Y, Kasajima R, Yamaguchi R, Uchida N, Konuma T, Tanaka M, Shingai N, Miyakoshi S, Kozai Y, Uehara Y, Eto T, Toyosaki M, Nishida T, Ishimaru F, Kato K, Fukuda T, Imoto S, Atsuta Y, Takahashi S. Mahine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation. Transplantation and Cellular Therapy. (In publication. 2024 Feb.) Kuwatuka Y and Kasajima R are the first equal contribution. IF=3.2
  6. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Morita J, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection. Anticancer Res 44(1):369-374, 2024. (Published 2024 Jan) IF=2.0
  7. Oshima T, Hashimoto I, Hiroshima Y, Kimura Y, Tanabe M, Onuma S, Nagasawa S, Kanematsu K, Aoyama T, Yamada T, Ogata T, Rino Y, Saito A, Miyagi Y. Clinical Significance of Chitinase-3-like Protein 1 Gene Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res 44(1):307-312. (Published 2024 Jan) IF=2.0
  8. Okubo Y, Sato S, Terao H, Yamamoto Y, Suzuki A, Hasegawa C, Yoshioka E, Ono K, Washimi K, Yokose T, Nakaigawa N, Kishida T, Miyagi Y. Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment. Arch Esp Urol 76(9):633-642, 2023. (Published 2023 Nov) IF=0.38
  9. Isaka T, Miyagi Y, Yokose T, Saito H, Kasajima R, Watabe K, Shigeta N, Kikunishi N, Shigefuku S, Murakami K, Adachi H, Nagashima T, Ito H. Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1-N2 epidermal growth factor receptor mutant lung adenocarcinoma. Transl Lung Cancer Res 12(10):2001-2014, 2023 (Published 2023 Oct 31)　IF＝2
  10. Li M, Nishimura T, Takeuchi Y, Hongu T, Wang Y, Shiokawa D, Wang K, Hirose H, Sasahara A, Yano M, Ishikawa S, Inokuchi M, Ota T, Tanabe M, Tada KI, Akiyama T, Cheng X, Liu CC, Yamashita T, Sugano S, Uchida Y, Chiba T, Asahara H, Nakagawa M, Sato S, Miyagi Y, Shimamura T, Nagai LAE, Kanai A, Katoh M, Nomura S, Nakato R, Suzuki Y, Tojo A, Voon DC, Ogawa S, Okamoto K, Foukakis T, Gotoh N. FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters. J Clin Invest 133(22):e166666, 2023 (Published 2023 Nov 15)　IF=15.9
  11. Takeuchi K, Tabe S, Takahashi K, Aoshima K, Matsuo M, Ueno Y, Furukawa Y, Yamaguchi K, Ohtsuka M, Morinaga S, Miyagi Y, Yamaguchi T, Tanimizu N, Taniguchi H. Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Cell Rep.;42(11):113420, 2023 (Published 2023 Nov 12) IF=8.8
  12. Saito Y, Nakamura S, Watanabe K, Ikegami H, Shinmura N, Sato S, Miyagi Y, Narimatsu H. Age group differences in psychological distress and leisure-time exercise/socioeconomic status during the COVID-19 pandemic: a cross-sectional analysis during 2020 to 2021 of a cohort study in Japan. Front Public Health 11:1233942, 2023 (Published 2023 Oct 25)　IF=3.3
  13. Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses. Cancer Commun (Lond) 44(2): 287-293, 2024 (Published 2024 Feb) IF=16.2
  14. Mezawa Y, Wang T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Yang L, Maruyama R, Seimiya H, Orimo A. Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. Cancer Sci 114(11):4376-4387, 2023 (Published 2023 Nov)　IF＝7
  15. Goto H, Ohtsu T, Ito M, Sagisaka M, Naruto T, Nagai JI, Kitagawa N, Tanaka M, Yanagimachi M, Hiroshima Y, Miyagi Y. A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors. Hum Cell 36(6):2152-2161, 2023 (Published 2023 Nov)　IF=4.3
  16. Sato S, Nakagawa M, Terashima T, Morinaga S, Miyagi Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S, Ueno M, Yamashita T, Koshikawa N. EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma. Cancer Res Commun 3(9):1862-1874, 2023. (Published 2023 Sep 15)　IF=11.2
  17. Hiratsuka T, Ito S, Sakai R, Yokose T, Endo T, Daigo Y, Miyagi Y, Tsuruyama T. Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins. Clin Proteomics 20(1):36, 2023 (Published 2023 Sep 13) IF=3.8
  18. Suzuki M, Kasajima R, Yokose T, Shimizu E, Hatakeyama S, Yamaguchi K, Yokoyama K, Katayama K, Yamaguchi R, Furukawa Y, Miyano S, Imoto S, Shinozaki-Ushiku A, Ushiku T, Miyagi Y. KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component. Transl Lung Cancer Res 12(8):1738-1751, 2023 (Published 2023 Aug 30) IF=4.0
  19. Suzuki MM, Iijima K, Ogami K, Shinjo K, Murofushi Y, Xie J, Wang X, Kitano Y, Mamiya A, Kibe Y, Nishimura T, Ohka F, Saito R, Sato S, Kobayashi J, Yao R, Miyata K, Kataoka K, Suzuki HI, Kondo Y. TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation. Nat Commun.;14(1):4521, 2023 (Published 2023 Aug 22)　IF=16.6
  20. Kawachi K, Tang X, Kasajima R, Yamanaka T, Shimizu E, Katayama K, Yamaguchi R, Yokoyama K, Yamaguchi K, Furukawa Y, Miyano S, Imoto S, Yoshioka E, Washimi K, Okubo Y, Sato S, Yokose T, Miyagi Y. Genetic analysis of low-grade adenosquamous carcinoma of the breast progressing to high-grade metaplastic carcinoma. Breast Cancer Res Treat 202(3):563-573, 2023 (Published 2023 Dec)　IF=3.8
  21. Koyama Y, Okazaki H, Shi Y, Mezawa Y, Wang Z, Sakimoto M, Ishizuka A, Ito Y, Koyama T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Sugahara K, Hino O, Yang L, Maruyama R, Katakura A, Yasukawa T, Orimo A. Increased RUNX3 expression mediates tumor-promoting ability of human breast cancer-associated fibroblasts. Cancer Med 12(17):18062-18077, 2023. (Published 2023 Sep) IF=4.0
  22. Okubo Y, Toda S, Sato S, Yoshioka E, Ono K, Hasegawa C, Washimi K, Yokose T, Miyagi Y, Iwasaki H, Hayashi H. Histological findings of thyroid cancer after lenvatinib therapy. Histopathology 83(4):657-663, 2023. (Published 2023 Oct)　IF=6.4
  23. Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. J Immunother Cancer 11(7):e006788, 2023. (Published 2023 July) IF=10.9
  24. Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, 52 authors, Miyagi Y, 158 authors, Kohno T, Lan Q. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat Commun 14(1):3043, 2023. (Published 2023 May 26)　IF=16.6
  25. Washimi K, Kasajima R, Shimizu E, Sato S, Okubo Y, Yoshioka E, Narimatsu H, Hiruma T, Katayama K, Yamaguchi R, Yamaguchi K, Furukawa Y, Miyano S, Imoto S, Yokose T, Miyagi Y. Histological markers, sickle-shaped blood vessels, myxoid area, and infiltrating growth pattern help stratify the prognosis of patients with myxofibrosarcoma/undifferentiated sarcoma. Sci Rep 13(1):6744, 2023. (Published 2023 Apr 25)　IF=5.0

2022年

  1. Sato S, Hiruma T, Koizumi M, Yoshihara M, Nakamura Y, Tadokoro H, Motomatsu S, Yamanaka T, Washimi K, Okubo Y, Yoshioka E, Kasajima R, Yamashita T, Kishida T, Yokose T, and Miyagi Y. Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance. Cancer Sci. In press. (2023 Mar)
  2. Koizume S, Kanayama T, Kimura Y, Hirano H, Takahashi T, Ota Y, Miyazaki K, Yoshihara M, Nakamura Y, Yokose T, Kato H, Takenaka K, Sato S, Tadokoro H, Miyagi E, Miyagi Y. Cancer cell-derived CD69 induced under lipid and oxygen starvation promotes ovarian cancer progression via fibronectin. Cancer Sci. Online ahead of print (2023 Feb)
  3. Okubo Y, Sato S, Hasegawa C, Koizumi M, Suzuki T, Yamamoto Y, Yoshioka E, Ono K, Washimi K, Yokose T, Kishida T, Miyagi Y. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores. Hum Pathol. Online ahead of print (2023 Feb )
  4. Matsuda Y, Ye J, Yamakawa K, Mukai Y, Azuma K, Wu L, Masutomi K, Yamashita T, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Kojima M, Kaneko S, Haba R, Kontani K, Kanaji N, Okano K, Muto-Ishizuka M, Yokohira M, Saoo K, Imaida K, Suizu F. Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worth prognosis. J Natl Cancer Inst 115(2):208-218, 2023. (Published 2023 Feb)
  5. Nagai K, Asano R, Sekiguchi F, Asai-Sato M, Miyagi Y, Miyagi E. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 228(2):207.e1-207.e9, 2023. (Published 2023 Feb)
  6. Wang X, Xiang H, Toyoshima Y, Shen W, Shichi S, Nakamoto H, Kimura S, Sugiyama K, Homma S, Miyagi Y, Taketomi A, Kitamura H. Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells. Cancer Metab 11(1):1, 2023. (Published 2023 Jan)
  7. Hasegawa C, Washimi K, Hiroshima Y, Kasajima R, Kikuchi K, Notomi T, Kato H, Hiruma T, Sato S, Okubo Y, Yoshioka E, Ono K, Miyagi Y, Yokose T. Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling. Diagn Pathol 18(1):5, 2023 (Published 2023 Jan)
  8. Natsume H, Szczepaniak K, Yamada H, Iwashita Y, Gędek M, Šuto J, Ishino K, Kasajima R, Matsuda T, Manirakiza F, Nzitakera A, Wu Y, Xiao N, He Q, Guo W, Cai Z, Ohta T, Szekely T, Kadar Z, Sekiyama A, Oshima T, Yoshikawa T, Tsuburaya A, Kurono N, Wang Y, Miyagi Y, Gurzu S, Sugimura H. Non-CpG sites preference in G:C > A:T transition of TP53 in gastric cancer of Eastern Europe (Poland, Romania and Hungary) compared to East Asian countries (China and Japan). Genes Environ 45(1):1, 2023. (Published 2023 Jan)
  9. Suematsu H, Sakamaki K, Oue N, Hiroshima Y, Kimura Y, Onuma S, Hashimoto I, Nagasawa S, Aoyama T, Yamada T, Tamagawa H, Ogata T, Rino Y, Masuda M, Yasui W, Miyagi Y, Oshima T. Clinical Significance of SEC11A Expression in Patients With Locally Advanced Gastric Cancer. Anticancer Res 42(12):5885-5890, 2022. (Published 2022 Dec)
  10. Koizumi M, Sato S, Yoshihara M, Nakamura Y, Terao H, Okubo Y, Washimi K, Yoshioka E, Yokose T, Kishida T, Koshikawa N, Miyagi Y. Chronological Change in EPHA2 Protein Expression Is Associated With Recurrence of Bladder Cancer. Anticancer Res 42(12):5783-5794, 2022. (Published 2022 Dec)
  11. Ota Y, Sato S, Yoshihara M, Nakamura Y, Miyagi E, Miyagi Y. A practical spatial analysis method for elucidating the biological mechanisms of cancers with abdominal dissemination in vivo. Sci Rep 12(1):20303, 2022. (Published 2022 Nov)
  12. Okubo Y, Yamamoto Y, Terao H, Suzuki T, Koizumi M, Yoshioka E, Washimi K, Sato S, Yokose T, Kishida T, Miyagi Y. Significance of non-standardized magnetic resonance imaging abnormalities and subsequent targeted prostate cancer biopsy for pathologists: A retrospective observational study. Pathol Res Pract 240:154188. (Published 2022 Dec)
  13. Hashimoto I, Kimura Y, Oue N, Hiroshima Y, Aoyama T, Rino Y, Yokose T, Yasui W, Miyagi Y, Oshima T. Identification of a Biomarker Combination for Survival Stratification in pStage II/III Gastric Cancer after Curative Resection. Cancers 14(18):4427, 2022. (Published 2022 Sep)
  14. Ikeda S, Kato T, Kenmotsu H, Ogura T, Sato Y, Hino A, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Kasajima R, Miyagi Y, Misumi T, Okamoto H. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. Oncologist 27(9):720-e702, 2022. (Published 2022 Sep)
  15. Shintaro Kazama, Kazuaki Yokoyama, Toshimitsu Ueki, Hiroko Kazumoto, Hidetoshi Satomi, Masahiko Sumi, Ichiro Ito, Nozomi Yusa, Rika Kasajima, Eigo Shimizu, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Arinobu Tojo, Hikaru Kobayashi. Case report: Common Clonal Origin of Concurrent Langerhans Cell Histiocytosis and Acute Myeloid Leukemia. Front Oncol 12:974307, 2022. (Published 2022 Sep)
  16. Ozaki A, Motomura H, Tamori S, Onaga C, Nagashima Y, Kotori M, Matsuda C, Matsuda A, Mochizuki N, Sato T, Hara Y, Sato K, Miyagi Y, Nagashima Y, Hanawa T, Harada Y, Xiong Y, Sasaki K, Ohno S, Akimoto K. High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Anticancer Res 42(7):3299-3312, 2022. (Published 2022 July)
  17. Suematsu H, Hashimoto I, Hiroshima Y, Watanabe H, Kano K, Takahashi K, Aoyama T, Yamada T, Tamagawa H, Ogata T, Yukawa N, Rino Y, Masuda M, Miyagi Y, Oshima T. Clinical Significance of EREG Gene Expression in Gastric Cancer Tissue After Curative Surgery. Anticancer Res 42(8):3873-3878, 2022. (Published 2022 Aug)
  18. Oshima T, Tsuburaya A, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Tan P, Grabsch HI, Sakamoto J, Tanaka S. Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial. Sci Rep 12(1):8509, 2022. (Published 2022 May)
  19. Azuma K, Xiang H, Tagami T, Kasajima R, Kato Y, Karakawa S, Kikuchi S, Imaizumi A, Matsuo N, Ishii H, Tokito T, Kawahara A, Murotani K, Sasada T, Miyagi Y, Hoshino T. Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model. J Immunother Cancer 10(5):e004420, 2022. (Published 2022 May)
  20. Koizume S, Takahashi T, Nakamura Y, Yoshihara M, Ohta Y, Sato S, Tadokoro H, Yokose T, Kato H, Miyagi E, Miyagi Y. Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma. British J Cancer 127(3):462-473, 2022. (Published 2022 Aug)
  21. Koizume S, Kobayashi S, Ruf W, Miyagi Y. Authors' reply to the Letter to the Editor: Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Sci 113(5):1888-1890, 2022. (Published 2022 May)
  22. Suzuki K, Igata H, Abe M, Yamamoto Y; small RNA based cancer classification project (Miyagi Y, Sato S and others). Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Sci 113(6):2144-2166, 2022. (Published 2022 Jun)
  23. Matsuda Y, Yamashita T, Ye J, Yasukawa M, Yamakawa K, Mukai Y, Machitani M, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Yamada S, Takei J, Kaneko MK, Kojima M, Kaneko S, Masaki T, Hirata M, Haba R, Kontani K, Kanaji N, Miyatake N, Okano K, Kato Y, Masutomi K. Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. J Pathol 257(2):172-185, 2022. (Published 2022 Jun)
  24. Okubo Y, Yamamoto Y, Sato S, Yoshioka E, Suzuki M, Washimi K, Osaka K, Suzuki T, Yokose T, Kishida T, Miyagi Y. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Arch 480(5):979-987, 2022. (published 2022 May)
  25. Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan AL, Hoppe MM, Jeyasekharan AD, Ng CCY, De Simone M, Grabsch HI, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 71(4):676-685, 2022. (published 2022 April)

2021年

  1. Suzuki K, Igata H, Abe M, Yamamoto Y, small RNA based cancer classification project (including Miyagi Y, Sato S and 24 Kanagawa Cancer Center doctors of multiple departments as authors). Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Sci (2022 Feb 14, in press)
  2. Takeda R, Yokoyama K, Fukuyama T, Kawamata T, Ito M, Yusa N, Kasajima R, Shimizu E, Ohno N, Uchimaru K, Yamaguchi R, Imoto S, Miyano S, Tojo A. Repeated lineage switches in an elderly case of refractory B-cell acute lymphoblastic leukemia with MLL gene amplification: A case report and literature review. Front Oncol (2022 Feb, in press)  
  3. Matsuda Y, Yamashita T, Ye J, Yasukawa M, Yamakawa K, Mukai Y, Machitani M, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Yamada S, Takei J, Kaneko MK, Kojima M, Kaneko S, Masaki T, Hirata M, Haba R, Kontani K, Kanaji N, Miyatake N, Okano K, Kato Y, Masutomi K. Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. J Pathol. (2022 Jan 30, Online ahead of print)
  4. Okubo Y, Yamamoto Y, Sato S, Yoshioka E, Suzuki M, Washimi K, Osaka K, Suzuki T, Yokose T, Kishida T, Miyagi Y. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Arch. (2022 Jan 11, Online ahead of print)
  5. Sugiyama K, Washimi K, Sato S, Hiruma T, Sakai M, Okubo Y, Miyagi Y, Yokose T. Differential diagnosis of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma by cytological analysis. Diagn Cytopathol. (2022 Jan 4, Online ahead of print)
  6. Hishida A, Yamada H, Ando Y, Okugawa Y, Shiozawa M, Miyagi Y, Daigo Y, Toiyama Y, Shirai Y, Tanaka K, Kubo Y, Okada R, Nagayoshi M, Tamura T, Mori A, Kondo T, Hamajima N, Takeuchi K, Wakai K. Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miR-26a-5p before clinical diagnosis. Oncol Lett 23(3):87, 2022. 2022 Mar
  7. Ida A, Okubo Y, Kasajima R, Washimi K, Sato S, Yoshioka E, Osaka K, Suzuki T, Yamamoto Y, Yokose T, Kishida T, Miyagi Y. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies. Pathol Res Pract 229:153731. 2022 Jan
  8. Yada E, Kasajima R, Niida A, Imoto S, Miyano S, Miyagi Y, Sasada T, Wada S. Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer. Biomedicines 9(10):1396, 2021. 2021 Oct　
  9. Hoshino D, Kato H, Fukumura K, Mayeda A, Miyagi Y, Seiki M, Koshikawa N. A novel LAMC2 fusion protein has tumor promoting properties in ovarian carcinoma. Cancer Sci 112(12):4957-4967, 2021. 2021 Dec
  10. Sueyoshi K, Komura D, Katoh H, Yamamoto A, Onoyama T, Chijiwa T, Isagawa T, Tanaka M, Suemizu H, Nakamura M, Miyagi Y, Aburatani H, Ishikawa S. Multi-tumor analysis of cancer-stroma interactomes of patient-derived xenografts unveils the unique homeostatic process in renal cell carcinomas. iScience 24(11):103322, 2021. 2021 Oct　
  11. Segami K, Aoyama T, Hiroshima Y, Komori K, Hashimoto I, Watanabe H, Kano K, Nagasawa S, Nakazono M, Maezawa Y, Fujikawa H, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Siozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Saeki H, Oshima T. Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer. In Vivo 35(5):2771-2777, 2021. 2021 Sep-Oct　
  12. Kobayashi S, Koizume S, Takahashi T, Ueno M, Oishi R, Nagashima S, Sano Y, Fukushima T, Tezuka S, Morimoto M, Nakamura S, Narimatsu H, Ruf W, Miyagi Y. Tissue Factor and its Procoagulant Activity on Cancer-Associated Thromboembolism in Pancreatic Cancer. Cancer Sci 112(11):4676-4691, 2021. 2021 Nov　
  13. Hiroshima K, Wu D, Koh E, Sekine Y, Ozaki D, Yusa T, Nakazawa T, Tsuji S, Miyagi Y, Walts AE, Marchevsky AM, Husain AN, Imai K. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas. Pathol Int 71(9):604-613, 2021. 2021 Sep
  14. Hatori S, Sakamaki K, Yokohori T, Kimura Y, Hiroshima Y, Hashimoto I, Komori K, Watanabe H, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Shiozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Saeki H, Miyagi Y, Oshima T. Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1. Anticancer Res 41(7):3583-3588, 2021. 2021 July　
  15. Tang X, Nakanishi Y, Kobayashi H, Nishimaki H, Kusumi Y, Miyagi Y, Masuda S. Mixed ductal-lobular carcinoma: an analysis of CDH1 DNA copy number variation and mutation. Breast Cancer 28(6):1318-1327, 2021. 2021 Nov　
  16. Motomura H, Ozaki A, Tamori S, Onaga C, Nozaki Y, Waki Y, Takasawa R, Yoshizawa K, Mano Y, Sato T, Sasaki K, Ishiguro H, Miyagi Y, Nagashima Y, Yamamoto K, Sato K, Hanawa T, Tanuma SI, Ohno S, Akimoto K. Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late-stage breast cancer. Oncol Lett 22(1):547, 2021. 2021 July 　
  17. Ono K, Kasajima R, Katayama K, Miyagi Y, Yokose T. Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin. Pathol Int 71(8):491-499, 2021. 2021 Aug　
  18. Miyagi E, Arakawa N, Sakamaki K, Yokota NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y, Kasamatsu Y, Kato H, Mogami T, Miyagi Y, Kobayashi H. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary. Miyagi E, Arakawa N, Sakamaki K, Yokota NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y, Kasamatsu Y, Kato H, Mogami T, Miyagi Y, Kobayashi H. Int J Clin Oncol 26(7):1336-1344, 2021. 2021 July          
  19. Yamaguchi K, Kasajima R, Takane K, Hatakeyama S, Shimizu E, Yamaguchi R, Katayama K, Arai M, Ishioka C, Iwama T, Kaneko S, Matsubara N, Moriya Y, Nomizu T, Sugano K, Tamura K, Tomita N, Yoshida T, Sugihara K, Nakamura Y, Miyano S, Furukawa Y, Ikenoue T. Application of targeted nanopore sequencing for the screening and determination of structural variants in patients with Lynch syndrome. J Hum Genet 66:1053–1060, 2021. 2021 May　
  20. Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan AL, Hoppe MM, Jeyasekharan AD, Ng CCY, De Simone M, Grabsch HI, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut gutjnl-2021-324060, 2021. 2021 May 　
  21. Sato S, Maki S, Yamanaka T, Hoshino D, Ota Y, Yoshioka E, Kawachi K, Washimi K, Suzuki M, Ohkubo Y, Yokose T, Yamashita T, Ohtori S, Miyagi Y. Machine learning-based image analysis for accelerating the diagnosis of complicated preneoplastic and neoplastic ductal lesions in breast biopsy tissues. Breast Cancer Res Treat 188(3):649-659. 2021 Aug 　
  22. Taniguchi H, Natori Y, Miyagi Y, Hayashi K, Nagamura F, Kataoka K, Imai K. Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex. Int J Cancer 149(3):646-656, 2021. 2021 Aug
  23. Suganuma N, Kawachi K, Yamashita T, Yamanaka T, Sugawara Y, Matsubara Y, Yamazaki Y, Kohagura K, Toda S, Okamoto S, Yoshida T, Rino Y, Masuda M, Narimatsu H, Fujita H, Yoshioka E, Yokose T, Furuta K, Miyagi Y. Quality Control of Breast Cancer Surgery Samples - Introducing Time Stamp Checking. Biopreserv Biobank 19(5):369-375, 2021. 2021 Oct　
  24. Watanabe T, Shiozawa M, Kimura Y, Hiroshima Y, Hashimoto I, Komori K, Watanabe H, Kano K, Fujikawa H, Aoyama T, Numata M, Yamada T, Tamagawa H, Ogata T, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Oshima T. Clinical significance of stanniocalcin2 mRNA expression in patients with colorectal cancer. Anticancer Res 41(4):2117-2122, 2021. 2021 April　
  25. Okubo Y, Sato S, Osaka K, Yamamoto Y, Suzuki T, Ida A, Yoshioka E, Suzuki M, Washimi K, Yokose T, Kishida T, Miyagi Y. Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters. Front Oncol 11:695251. 2021 July　
  26. Hiroshima K, Wu D, Hamakawa S, Tsuruoka S, Ozaki D, Orikasa H, Hasegawa M, Koh E, Sekine Y, Yonemori Y, Nabeshima K, Tsuji S, Miyagi Y, Imai K. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion. Diagn Cytopathol 49(5):622-632, 2021. 2021 May　
  27. Toda S, Sato S, Saito S, Sekihara K, Matsui A, Murayama D, Nakayama H, Suganuma N, Okubo Y, Hayashi H, Iwasaki H, Miyagi Y and Hoshino D. TROP-2,Nectin-4,GPNMB, and B7-H3 are potentially therapeutic targets for anaplastic thyroid carcinoma. Cancers, 2022 in press
  28. Nagasawa S, Tsuchida K, Shiozawa M, Hiroshima Y, Kimura Y, Hashimoto I, Watanabe H, Kano K, Numata M, Aoyama T, Sato S, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Morinaga S, Yukawa N, Rino Y, Masuda M, Saeki H, Miyagi Y, Oshima T. Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer. Anticancer Res. 2021 Sep;41(9):4489-4495. doi: 10.21873/anticanres.15259. PMID: 34475074.

特許等

  1. 発明の名称:PRDM14発現を確認する方法
    出願番号:特願2017-185200
    出願日:2017年9月26日
    発明者:
    地独県立病院機構神奈川県立がんセンター:宮城 洋平
    東京大学医科学研究所:今井 浩三、谷口 博昭、斎藤 杏里
    国立がん研究センター研究所:前沸 均
  2. 発明の名称:がんリスク評価法及びがんリスク評価システム
    出願番号:特願2017-186273
    出願日:2017年9月26日
    発明者:
    地独県立病院機構神奈川県立がんセンター:宮城 洋平
    株式会社レナテック:稲垣 精一、岡本 直幸
    千葉県がんセンター研究所:三上 春夫

スタッフ紹介

　

※メールアドレスの[at]は＠に直してご送信ください。

  • 宮城 洋平みやぎ ようへい

    役職 部長
    Eメール miyagi.0e82r[at]kanagawa-pho.jp
    専門 分子腫瘍学、腫瘍病理学

  • 小井詰 史朗こいづめ しろう

    役職 主任研究員
    Eメール koizume.2230b[at]kanagawa-pho.jp
    専門 分子生物学、分子腫瘍学

  • 佐藤 慎哉さとう しんや

    役職 医長
    Eメール sato.0f80j[at]kanagawa-pho.jp
    専門 病理学、分子生物学、腫瘍学（がん転移）、EV

  • 笠島 理加かさじま りか

    役職 主任研究員（がんゲノム診療センター）
    Eメール kasajima.4080j[at]kanagawa-pho.jp
    専門 がんゲノム解、分子腫瘍学

  • 項 慧慧Xiang Huihui

    役職 特任研究員
    Eメール shan.5430k[at]kanagawa-pho.jp
    専門 分子腫瘍学, 腫瘍免疫学

  • 中村 圭靖なかむら よしやす

    役職 専門検査技師
    Eメール nakamura.0c52e[at]kanagawa-pho.jp

  • 高橋 朋子たかはし ともこ

    役職 研究補助員

  • 小森 由香子こもり ゆかこ

    役職 研究補助員

  • 大類 久美子おおるい くみこ

    役職 研究補助員

  • 中川 仁美なかがわ ひとみ

    役職 研究補助員
    Eメール nakagawa.hy20n@kanagawa-pho.jp

  • 依田 和美よだ かずみ

    役職 事務補助員
    Eメール yoda.5180b[at]kanagawa-pho.jp

  • 竹中 克也たけなか かつや

    役職 受入研究員 （新日本科学TRカンパニー）

  • 宮崎 香みやざき かおる

    役職 客員研究員（横浜市立大学名誉教授）

  • 川本 進かわもと すすむ

    役職 客員研究員（千葉大学 名誉教授）

  • 増永 敦子ますなが あつこ

    役職 客員研究員 （東京女子医科大学足立医療センター教授）

  • 田所 弘子たどころ ひろこ

    役職 客員研究員 （東京薬科大学薬学部）

  • 谷岡 沙紀たにおか さき

    役職 研究生 （横浜市大医学部大学院）

  • 魚本 真理うおもと まり

    役職 研究生 （大和市立病院）

Contact

045-520-2222（代表）

受付時間 9:00～17:00（平日のみ）

お問い合わせ